Skip to main content
Clinical Trials/ISRCTN89615545
ISRCTN89615545
Completed
未知

REmission MEchanisms in Depression

niversity of Manchester (UK)0 sites72 target enrollmentApril 29, 2010

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Manchester (UK)
Enrollment
72
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Published conference abstracts: 2009 results in: https://doi.org/10.1016/S0924-977X(09)70565-6 (added 26/11/2019) 2009 results in: https://doi.org/10.1016/S0924-977X(09)70594-2 (added 26/11/2019) 2009 results in: Arnone D, Pegg EJ, McKie S, Downey D, Elliott R, Williams SR, Deakin JFW, Anderson IM (2009) Current major depression but not remitted major depression shows increased neural responses to sad facial expressions. Journal of Psychopharmacology Suppl to Vol 23(6), A26 (added 26/11/2019) 2009 results in: Pegg EJ, Arnone D, McKie S, Elliott R, Deakin JFW, Anderson IM (2009) Citalopram treatment increases neural responses to positive words and decreases responses to negative words in depression. Journal of Psychopharmacology Suppl to Vol 23(6), A25 (added 26/11/2019) Refereed papers: 2012 results in: https://www.ncbi.nlm.nih.gov/pubmed/22854930 (added 26/11/2019) 2013 results in: https://www.ncbi.nlm.nih.gov/pubmed/23128153 (added 26/11/2019) 2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/30877271 (added 26/11/2019)

Registry
who.int
Start Date
April 29, 2010
End Date
May 31, 2010
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Manchester (UK)

Eligibility Criteria

Inclusion Criteria

  • Depressed subjects:
  • 1\. DSM\-IV major depressive episode with a Montgomery Asberg Depression Rating Scale (MADRS) score greater than 20
  • 2\. Psychotropic drug\-free for greater than 2 weeks (2 months for fluoxetine)
  • 3\. Psychiatrically well
  • 4\. Good physical health
  • 5\. Aged 18 \- 55 years, either sex

Exclusion Criteria

  • Depressed subjects:
  • 1\. Duration of depressive episode greater than 1 year or depression superimposed on dysthymia
  • 2\. Failure to respond to 2 antidepressants given for 6 weeks at an adequate dose in current episode
  • 3\. Failure to respond to citalopram or escitalopram in current episode
  • 4\. Allergy or intolerance to citalopram or escitalopram
  • 5\. Contraindications to selective serotonin reuptake inhibitor (SSRI) treatment (e.g., history of peptic ulcer/gasterointestinal \[GI] bleeding or taking non\-steroidal anti\-inflammatory drugs \[NSAIDs], in the absence of concurrent ulcer\-protective treatment)
  • 6\. Other concurrent psychotropic medication except for small stable doses of short acting hypnotics
  • 7\. Electroconvulsive therapy (ECT) or lithium in current episode
  • 8\. Significant suicidal risk or likely need for other psychiatric intervention during the study period
  • 9\. Other current co\-morbid Axis I psychiatric disorders except anxiety disorders (excluding OCD) secondary to depression

Outcomes

Primary Outcomes

Not specified

Similar Trials